AstraZeneca and Bina Technologies, Inc., a member of the Roche Group, today announced that they have entered into an agreement for AstraZeneca to become the first member to join the Bina Alliance Programme and to further develop the Bina Genomic Management Solution (GMS).
AstraZeneca will utilise the Bina GMS to support its development work across its main therapeutic areas of respiratory, inflammation and autoimmunity, cardiovascular and metabolic disease, and oncology.
Bina’s proprietary technology enables translational and academic researchers to perform fast and scalable analyses to maximise the value of genomic data. Under the terms of the agreement, AstraZeneca will adopt Bina GMS globally to support genomic data analysis and management. Bina will provide AstraZeneca with direct access to its scientific and engineering teams to further develop the Bina GMS for pharmaceutical applications.
Dr. Carl Barrett, Vice President, Translational Oncology, at AstraZeneca, said: “Bina GMS is a powerful data analysis platform that will help AstraZeneca leverage more effectively genomic data across all phases of our research globally as we develop personalised therapies to treat complex diseases.”
Justin Johnson, Principal Translational Genomic Scientist at AstraZeneca, added: “In working with Bina, we can not only significantly accelerate the speed in which we incorporate genomic data into areas like target discovery and patient selection, but we can do this on top of a flexible, scalable and validated analysis infrastructure that our bench scientists can work with.” Johnson will be presenting early results of the collaboration during the Cambridge Healthtech Institute’s 14th Annual Bio-IT World Conference and Expo (Bio-IT) in Boston, MA on Thursday 23 April.
“We are very excited about the work we are doing with the AstraZeneca team,” said Dr. Narges Bani Asadi, CEO and Founder of Bina. “In this collaboration, our multidisciplinary team of scientists and engineers will try to push the boundaries of genomics research. We are very fortunate to be able to contribute to the research at AstraZeneca. Through this collaboration we both hope to define a new standard for the pharmaceutical research industry in how to effectively leverage the genomic information for discovery and development.”
 Bina products are for research use only and not for use in diagnostic procedures